Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

No abstract is available for this paper.

• Publication year

  2003

• Venue

  European Respiratory Journal

• Publication date

  2003-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09031936.03.00045202PMID 12570122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EXPLANATORY AND PRAGMATIC ATTITUDES IN THERAPEUTICAL TRIALS

  2003cited by this paper
• Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.

  2001cited by this paper
• Psychometric evaluation of the CAP-Sym questionnaire: A new, patient-based measure of symptoms in community acquired pneumonia

  2001cited by this paper
• Reassuring safety profile of moxifloxacin.

  2001cited by this paper
• New Milestones Achieved in Fluoroquinolone Safety

  2001cited by this paper
• Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

  2001cited by this paper
• Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.

  2000cited by this paper
• Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

  2000cited by this paper
• Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia.

  2000cited by this paper
• Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.

  2000cited by this paper
• Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.

  1999cited by this paper
• Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

  1999cited by this paper
• Trends in infectious disease mortality in the United States during the 20th century.

  1999cited by this paper
• Can it work? Does it work? Is it worth it?

  1999cited by this paper
• Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke.

  1999cited by this paper
• The cost of treating community-acquired pneumonia.

  1998cited by this paper
• Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia

  1998cited by this paper
• A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.

  1998cited by this paper
• Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.

  1998cited by this paper
• Guidelines for management of adult community-acquired lower respiratory tract infections

  1998cited by this paper
• Understanding controlled trials: What are pragmatic trials?

  1998cited by this paper
• Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

  1997cited by this paper
• Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.

  1997cited by this paper
• A prediction rule to identify low-risk patients with community-acquired pneumonia.

  1997cited by this paper
• The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study.

  1997cited by this paper
• Incidence of Community-Acquired Pneumonia Requiring Hospitalization Results of a Population-Based Active Surveillance Study in Ohio

  1997cited by this paper
• A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

  1997cited by this paper
• The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study.

  1997cited by this paper
• Generalisation from phase III clinical trials: survival, quality of life, and health economics.

  1997cited by this paper
• Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.

  1996cited by this paper
• Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

  1996cited by this paper
• Trends in infectious diseases mortality in the United States.

  1996cited by this paper
• Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.

  1995cited by this paper
• From clinical trials to clinical practice: generalizing from participant to patient.

  1994cited by this paper
• Generalizing the results of randomized clinical trials.

  1994cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• Introduction to Table V. Premature deaths, monthly mortality, and monthly physician contacts--United States.

  1982cited by this paper
• Explanatory and pragmatic attitudes in therapeutical trials.

  1967cited by this paper

• Cephalexin-loaded polyvinyl alcohol/graphene oxide thin films as antibacterial wound dressing

  2026cites this paper
• Appropriateness of antimicrobial selection for treatment of pneumonia in selected public hospitals of Eastern Ethiopia: A cross-sectional study

  2023cites this paper
• Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial

  2023cites this paper
• Empirical Antibiotic Treatment Strategies for Community-Acquired Pneumonia: A Network Meta-analysis.

  2022cites this paper
• Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review

  2021cites this paper
• Skin and soft tissue infections

  2021cites this paper
• Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

  2020cites this paper
• One-Year Quality of Life Post–Pneumonia Diagnosis in Japanese Adults

  2020cites this paper
• Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population

  2019cites this paper
• Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.

  2019influential citation
• Antimicrobial Stewardship Program Perspective: IV-to-PO Switch Therapy.

  2018cites this paper
• Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia

  2018cites this paper
• Antibiotic Stewardship Program Perspective: Oral Antibiotic Therapy for Common Infectious Diseases.

  2018cites this paper
• The impact of community-acquired pneumonia on the health-related quality-of-life in elderly

  2017cites this paper
• The Nephroprotective Effect of Folic Acid-Only a Matter of Homocysteine?

  2017cites this paper
• Validation of IDSA/ATS Algorithm for Duration of Pneumonia Therapy-Reply.

  2017cites this paper
• A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days

  2017cites this paper
• Antimicrobial Therapy for Legionnaire's Disease: Antibiotic Stewardship Implications.

  2017cites this paper
• Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.

  2016cites this paper
• Empirical Antibiotic Treatment for Community-acquired Pneumonia: New Perspectives

  2015cites this paper
• Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.

  2015cites this paper
• Managing CAP patients at risk of clinical failure.

  2015cites this paper
• Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

  2014cites this paper
• Gender Analysis of Moxifloxacin Clinical Trials

  2014cites this paper
• Antibiotics for community-acquired pneumonia in adult outpatients.

  2014cites this paper
• Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?

  2013cites this paper
• Moxifloxacin-associated neutropenia

  2013cites this paper
• New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.

  2012cites this paper
• Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections

  2012cites this paper
• Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

  2012cites this paper
• Fluoroquinolones Reported Hepatotoxicity

  2012cites this paper
• Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials

  2012cites this paper
• Are Fluoroquinolones Superior Antibiotics for the Treatment of Community-Acquired Pneumonia?

  2012cites this paper
• Moxifloxacin

  2012cites this paper
• Guidelines for the management of adult lower respiratory tract infections--summary.

  2011cites this paper
• Krankheitskosten sowie gesundheitsbezogene Lebensqualität (hrQoL) bei ambulant erworbener Pneumonie (CAP) – ein systematisches Review

  2011cites this paper
• Pleural Fluid Analysis in Chylothorax

  2011cites this paper
• Klinické doporu čení: Diagnostika a lé čba komunitní pneumonie

  2011cites this paper
• Guidelines for the management of adult lower respiratory tract infections ‐ Full version

  2011cites this paper
• STUDY OF CURRENT MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AND STRATEGIES FOR IMPROVEMENT

  2011cites this paper
• Fluoroquinolones in the management of community-acquired pneumonia in primary care

  2010cites this paper
• Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy

  2009cites this paper
• 10 years’ experience with the pneumococcal quinolone moxifloxacin

  2009cites this paper
• Duration of antibiotic treatment and symptom recovery in community-acquired pneumonia

  2009cites this paper
• British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009

  2009cites this paper
• Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin

  2009cites this paper
• BTS guidelines for the management of community acquired pneumonia in adults: update 2009

  2009cites this paper
• Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?

  2009cites this paper
• Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines

  2009cites this paper
• Antibiotics for community acquired pneumonia in adult outpatients.

  2009cites this paper
• Moxifloxacin: a respiratory fluoroquinolone

  2008cites this paper
• Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia

  2008cites this paper
• Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.

  2008cites this paper
• Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

  2008influential citation
• What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.

  2008cites this paper
• Clinical end points of therapy for patients with mild community-acquired pneumonia.

  2008cites this paper
• At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.

  2008cites this paper
• Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

  2008cites this paper
• A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium

  2008cites this paper
• Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.

  2008cites this paper
• Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?

  2008cites this paper
• Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

  2008cites this paper
• Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.

  2007cites this paper
• A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)

  2007cites this paper
• Management of community-acquired respiratory tract infections in an era of increasing antibiotic resistance

  2006cites this paper
• Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

  2006cites this paper
• Duration of antibiotic treatment and symptom recovery in community-acquired pneumonia

  2006cites this paper
• Quel antibiotique pour une pneumonie aiguë communautaire de l'adulte ?

  2006cites this paper
• Pneumonies aiguës communautaires : analyse critique des essais cliniques

  2006cites this paper
• Moxifloxacin in the treatment of elderly patients with community-acquired pneumonia

  2006cites this paper
• [Antibiotherapy for acute CAP in adults].

  2006cites this paper
• New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited.

  2006cites this paper
• Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia

  2006cites this paper
• Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

  2006cites this paper
• Oral antibiotic therapy of serious systemic infections.

  2006cites this paper
• Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia

  2006cites this paper
• [Acute community-acquired pneumonia. A review of clinical trials].

  2006cites this paper
• rinciples of antibiotic treatment of community-acquired neumonia in the outpatient setting

  2005cites this paper
• Cost analyses of community-acquired pneumonia from the hospital perspective.

  2005cites this paper
• Efficacy and Tolerability of Sequential Intravenous/Oral Moxifloxacin Therapy in Pneumonia

  2005cites this paper
• Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.

  2005cites this paper
• Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors

  2005cites this paper
• Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.

  2005cites this paper
• Moxifloxacin and Ciprofloxacin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in Vitro

  2005cites this paper
• Moxifloxacin in respiratory tract infections

  2005cites this paper
• The Integrated Use of Pharmacokinetic and Pharmacodynamic Models for the Definition of Breakpoints

  2005cites this paper
• Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.

  2005cites this paper
• Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

  2005cites this paper
• Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin.

  2005cites this paper
• Moxifloxacin and Azithromycin but not Amoxicillin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae In Vitro when Administered up to 6 Hours after Challenge

  2005cites this paper
• Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.

  2004cites this paper
• ▼Moxifloxacin - a new fluoroquinolone antibacterial

  2004cites this paper
• Alpha 1-antitrypsin: more than just deficiency.

  2004cites this paper
• Nieuwe fluorochinolonen: levofloxacine, moxifloxacine en gatifloxacine

  2004cites this paper
• Sleep disordered breathing and the outcome of stroke

  2004cites this paper
• Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis.

  2004cites this paper
• Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.

  2004cites this paper
• Management of respiratory infections in the elderly

  2003cites this paper
• Terms and Conditions for Use of Pdf

  year unknowncites this paper
• UvA-DARE (Digital Academic Repository) Development and validation of a short questionnaire in community acquired pneumonia

  year unknowncites this paper